<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02289235</url>
  </required_header>
  <id_info>
    <org_study_id>CT-P-9364-6254</org_study_id>
    <nct_id>NCT02289235</nct_id>
  </id_info>
  <brief_title>Effects of Ginger on Nonalcoholic Fatty Liver Disease in T2DM</brief_title>
  <acronym>GinLivDM</acronym>
  <official_title>The Effects of Ginger on Biochemical Markers and Imaging Studies of Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to evaluate the effects and safety of ginger in treatment of
      nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ginger (Zingiber officinale Roscoe) has been cultivated for medicinal and culinary purposes
      for at least two millennia. It contains several hundred valuable compounds and new
      constituents are still being found. Ginger's high antioxidant value has proved highly
      effective with its ability to scavenge a number of free radicals and protect cell membrane
      lipids from oxidation in a dose-dependent manner.

      In a randomized double-blind placebo-controlled clinical trial, the investigators want to
      investigate the effects of ginger in treatment of nonalcoholic fatty liver disease (NAFLD) in
      patients with type 2 diabetes mellitus (T2DM).
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ALT (liver transaminases) level</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Change in the concentration of ALT (liver transaminases)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in score of fatty liver in fibroscan</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Change in score of fatty liver in fibroscan (elastography)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in AST (liver transaminases) level</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Change in the concentration of AST (liver transaminases)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gama GT (γ-glutamyl transpeptidase) levels</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>Change in the concentration of Gama GT (γ-glutamyl transpeptidase)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>4 months</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Fatty Liver</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Ginger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ginger powder capsule 500 mg daily for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo powder 1 capsule daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ginger</intervention_name>
    <description>Ginger powder capsule 500 mg daily for 3 months</description>
    <arm_group_label>Ginger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo powder 1 capsule daily for 3 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Controlled type 2 diabetes mellitus (HbA1c&lt;7%)

          -  Age: 20-65 years

          -  Body mass index: 18-35 kg/m2

          -  Serum ALT level: &gt;60 U/Lit. in males, &gt;38 U/Lit. in females

          -  Grade &gt;=2 fatty liver in liver sonography

        Exclusion Criteria:

          -  Pregnancy

          -  Acute or chronic liver failure

          -  Acute or chronic renal failure

          -  Autoimmune or viral hepatitis

          -  Wilson's disease

          -  Alcoholism

          -  Malignancy

          -  Hypothyroidism or hyperthyroidism

          -  Drug used in last three months: OCP, vitamin E, ursodeoxycholic acid, glucocorticoids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mesbah Shams, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Majid Nimruzi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Center for Traditional Medicine, Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kamran Bagheri Lankarani, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health policy Research Center, Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Parisa-sadaat Ghoreishi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shahid Motahhari Clinic, Shiraz University of Medical Sciences</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 7, 2014</study_first_submitted>
  <study_first_submitted_qc>November 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2014</study_first_posted>
  <last_update_submitted>April 5, 2019</last_update_submitted>
  <last_update_submitted_qc>April 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mesbah Shams, MD</investigator_full_name>
    <investigator_title>Associate professor of Internal Medicine &amp; Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Ginger</keyword>
  <keyword>Medicine, traditional</keyword>
  <keyword>Herbal medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

